Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novo Nordisk A/S (NVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 115,209,000
  • Shares Outstanding, K 2,550,000
  • Annual Sales, $ 16,611 M
  • Annual Income, $ 5,636 M
  • 36-Month Beta 0.63
  • Price/Sales 7.24
  • Price/Cash Flow 19.44
  • Price/Book 16.14

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.03 +10.11%
on 07/27/17
46.86 -3.59%
on 08/16/17
+1.99 (+4.61%)
since 07/18/17
3-Month
40.78 +10.79%
on 05/19/17
46.86 -3.59%
on 08/16/17
+4.74 (+11.72%)
since 05/18/17
52-Week
30.89 +46.26%
on 11/23/16
47.98 -5.84%
on 08/22/16
-1.86 (-3.95%)
since 08/18/16

Most Recent Stories

More News
The Zacks Analyst Blog Highlights: Pfizer, TJX Companies, Honda, American Electric and Novo Nordisk

The Zacks Analyst Blog Highlights: Pfizer, TJX Companies, Honda, American Electric and Novo Nordisk

TJX : 70.47 (+0.31%)
NVO : 45.18 (-0.35%)
AEP : 72.16 (+0.22%)
PFE : 32.67 (-0.85%)
HMC : 27.54 (+0.66%)
United States Antidiabetics Drug Market Outlook 2017-2022 - Market is Dominated by Three Key Players - Eli Lilly, Novo Nordisk, and Sanofi

The "US Antidiabetics Drug Market Outlook 2022" report has been added to Research and Markets' offering.

NVO : 45.18 (-0.35%)
LLY : 77.07 (-0.94%)
Novo Nordisk's Semaglutide Shows Remarkable Results in Study

Novo Nordisk (NVO) pipeline candidate shows superior glucose control and weight loss in study in diabetes patients compared with Eli Lilly and Co's Trulicity (dulaglutide).

NVO : 45.18 (-0.35%)
LLY : 77.07 (-0.94%)
REGN : 467.98 (+0.85%)
ALXN : 133.40 (-0.91%)
Top Analyst Reports for Pfizer, TJX Companies & Honda

Top Analyst Reports for Pfizer, TJX Companies & Honda

TJX : 70.47 (+0.31%)
NVO : 45.18 (-0.35%)
AEP : 72.16 (+0.22%)
PXD : 131.95 (+0.52%)
PFE : 32.67 (-0.85%)
HMC : 27.54 (+0.66%)
Semaglutide superior to dulaglutide on glucose control and weight loss in people with type 2 diabetes in SUSTAIN 7

Bagsvaerd, Denmark, 16 August 2017 - Novo Nordisk today announced the SUSTAIN 7 trial results, demonstrating that people with type 2 diabetes treated with once-weekly semaglutide experienced superior reduction...

NVO : 45.18 (-0.35%)
Novo Nordisk announces changes in executive management

Danish pharmaceutical company Novo Nordisk A/S (CPH:NOVOB) announced on Tuesday the appointment of Camilla Sylvest as executive vice president in charge of Commercial Strategy & Corporate Affairs, effective...

NVO : 45.18 (-0.35%)
Breakfast Technical Briefing on Drug Makers Stocks -- Depomed, Synergy Pharma, Novo Nordisk, and SciClone Pharma

If you want a Stock Review on DEPO, SGYP, NVO, or SCLN then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. DailyStockTracker.com has issued research...

SCLN : 11.10 (+0.45%)
NVO : 45.18 (-0.35%)
SGYP : 2.91 (+0.34%)
DEPO : 6.55 (+3.97%)
The Zacks Analyst Blog Highlights: Deutsche Bank, Novo Nordisk, SINA, Weibo and GOL Linhas Aereas Inteligentes

The Zacks Analyst Blog Highlights: Deutsche Bank, Novo Nordisk, SINA, Weibo and GOL Linhas Aereas Inteligentes

GOL : 15.42 (+2.32%)
NVO : 45.18 (-0.35%)
WB : 89.68 (+1.54%)
DB : 16.52 (+0.49%)
SINA : 98.40 (+0.24%)
Insulin Delivery Devices Market to Reach US$20.9 Billion by 2025; Growing Prevalence of Diabetes Driving Demand

As per the findings of a recent study by Transparency Market Research (TMR), the global insulin delivery devices market is largely fragmented, owing to the presence of a number of global players as well...

NVO : 45.18 (-0.35%)
LLY : 77.07 (-0.94%)
MDT : 83.41 (-0.31%)
Foreign Stock Roundup: Novo Nordisk, GOL Linhas Beat on Earnings

Global markets were weighed down by the deterioration in U.S.-North Korea relations over last week.

GOL : 15.42 (+2.32%)
NVO : 45.18 (-0.35%)
NXTM : 29.25 (+0.03%)
MZDAY : 7.3900 (+1.23%)
TM : 111.73 (+0.25%)
WB : 89.68 (+1.54%)
FMS : 46.38 (-0.19%)
DB : 16.52 (+0.49%)
BP : 34.16 (+0.18%)
SINA : 98.40 (+0.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural...

See More

Support & Resistance

2nd Resistance Point 45.41
1st Resistance Point 45.30
Last Price 45.18
1st Support Level 45.07
2nd Support Level 44.96

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.